(Q38060459)

30 June 2019

review article

2 references

2 May 2021

Ivabradine: an intelligent drug for the treatment of ischemic heart disease (English)

1 reference

30 June 2019

1 reference

2 May 2021

1 reference

2 May 2021

Graziano Riccioni

1

1 reference

30 June 2019

language of work or name

English

0 references

publication date

16 November 2012

2 references

30 June 2019

2 May 2021

2 references

30 June 2019

2 May 2021

17

1 reference

30 June 2019

issue

11

1 reference

30 June 2019

page(s)

13592-13604

1 reference

30 June 2019

Creative Commons Attribution 3.0 Unported

copyright license

1 reference

Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction

2 May 2021

0 references

1 reference

12 December 2020

Cardiac HCN channels: structure, function, and modulation

1 reference

12 December 2020

Heart rate correction of the QT duration in rats

1 reference

12 December 2020

Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina

1 reference

12 December 2020

Safety and effectiveness of ivabradine after cardiac transplantation

1 reference

12 December 2020

How does adrenaline accelerate the heart?

1 reference

12 December 2020

Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial

1 reference

12 December 2020

[Ivabradine - a new therapeutic option for cardiogenic shock?].

1 reference

12 December 2020

Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease

1 reference

12 December 2020

The cardiac pacemaker current

1 reference

12 December 2020

Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities

1 reference

12 December 2020

Novel If current inhibitor ivabradine: safety considerations

1 reference

12 December 2020

The biological effects of ivabradine in cardiovascular disease.

1 reference

12 December 2020

Ivabradine for the treatment of stable angina pectoris in octogenarians

1 reference

12 December 2020

Can we improve cardiovascular risk prediction beyond risk equations in the physician's office?

1 reference

12 December 2020

Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial

1 reference

12 December 2020

Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases

1 reference

12 December 2020

Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina

1 reference

12 December 2020

Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).

1 reference

12 December 2020

Clinical pharmacology of two specific bradycardiac agents

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers.

1 reference

12 December 2020

HCN channels: structure, cellular regulation and physiological function

1 reference

12 December 2020

Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study

1 reference

12 December 2020

Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus

1 reference

12 December 2020

HCN-related channelopathies.

1 reference

12 December 2020

Electrophysiological Effects of a Single Intravenous Administration of Ivabradine (S 16257) in Adult Patients with Normal Baseline Electrophysiology

1 reference

12 December 2020

Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine

1 reference

12 December 2020

Muscarinic control of the hyperpolarization-activated current (if) in rabbit sino-atrial node myocytes

1 reference

12 December 2020

Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial

1 reference

12 December 2020

I f inhibition with ivabradine : electrophysiological effects and safety

1 reference

12 December 2020

Inhibitory actions of ZENECA ZD7288 on whole-cell hyperpolarization activated inward current (If) in guinea-pig dissociated sinoatrial node cells

1 reference

12 December 2020

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy

1 reference

12 December 2020

The funny current: cellular basis for the control of heart rate.

1 reference

12 December 2020

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

1 reference

12 December 2020

Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia.

1 reference

12 December 2020

Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers

1 reference

12 December 2020

Exploring HCN channels as novel drug targets

1 reference

12 December 2020

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

1 reference

12 December 2020

Acetylcholine inhibits activation of the cardiac hyperpolarizing-activated current, if.

1 reference

12 December 2020

Focus on ivabradine: a new heart rate-controlling drug

1 reference

12 December 2020

The role of the funny current in pacemaker activity.

1 reference

12 December 2020

Ivabradine improves all aspects of quality of life assessed with the 36-item short form health survey in subjects with chronic ischemic heart disease compared with beta-blockers

1 reference

12 December 2020

The contribution of the 'pacemaker' current (if) to generation of spontaneous activity in rabbit sino-atrial node myocytes

1 reference

12 December 2020

Hyperpolarization-activated cation channels: from genes to function

1 reference

12 December 2020

Treatment strategies for chronic stable angina

1 reference

12 December 2020

Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings

1 reference

12 December 2020

Use- and frequency-dependent blockade by UL-FS 49 of the if pacemaker current in sheep cardiac Purkinje fibres

1 reference

12 December 2020

A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction

1 reference

12 December 2020

Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction

1 reference

12 December 2020

Resting heart rate in cardiovascular disease

1 reference

12 December 2020

Ivabradine: recent and potential applications in clinical practice

1 reference

12 December 2020

HCN channelopathies: pathophysiology in genetic epilepsy and therapeutic implications

1 reference

12 December 2020

Funny channel-based pacemaking

1 reference

12 December 2020

The pacemaker current: from basics to the clinics.

1 reference

12 December 2020

HCN channels and heart rate

1 reference

12 December 2020

Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure

1 reference

12 December 2020

Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography

1 reference

12 December 2020

Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity

1 reference

12 December 2020

Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure

1 reference

12 December 2020

Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial

1 reference

12 December 2020

N-Allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site

1 reference

12 December 2020

Cellular mechanisms underlying the pharmacological induction of phosphenes

1 reference

12 December 2020

Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs.

1 reference

12 December 2020

Ivabradine: from molecular basis to clinical effectiveness

1 reference

12 December 2020

10.3390/MOLECULES171113592

Identifiers

DOI

1 reference

30 June 2019

PMC publication ID

6268242

1 reference

30 June 2019

PubMed publication ID

23159921

1 reference

30 June 2019